Medicare Expenditures in the First Year of Amyotrophic Lateral Sclerosis Diagnosis
Approximately one-third of people with ALS on Medicare receive disease-modifying medication. ALS is a burdensome disease with significant financial implications for people with ALS and the Medicare program. Treatment for ALS presents affordability challenges, and policy makers must consider how current Medicare policy addresses the costs of care.
Authors
- Sarah Parvanta (ORCID: https://orcid.org/0000-0003-3432-5535)
- Neil Thakur (ORCID: https://orcid.org/0000-0003-2099-3364)
- Alexis J. Feuer
- Cheryl Seals (ORCID: https://orcid.org/0000-0002-6701-666X)
- Marisa Aurora (ORCID: https://orcid.org/0000-0003-2478-4009)
- Melissa Morley
- Kuldip D. Dave
- Kolton Gustafson
- Sana Datar
Institutions
- Prevea Health (US)
Publication Details
- Journal
- The American Journal of Managed Care
- Published
- 2025-10-20
- DOI
- https://doi.org/10.37765/ajmc.2025.89813
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00